Plus Therapeutics, Inc.
General ticker "PSTV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.3K (TTM average)
Plus Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -21.7%.
Estimated limits based on current volatility of 4.4%: low 3.75$, high 4.10$
Factors to consider:
- Total employees count: 28 as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Inability to achieve profitability, Clinical trial failure, Regulatory and compliance, Labor/talent shortage/retention
- Current price 51.9% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.78$, 24.67$]
- 2026-12-31 to 2027-12-31 estimated range: [5.44$, 18.28$]
Financial Metrics affecting the PSTV estimates:
- Positive: with PPE of -9.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 1.26 <= 3.34
- Positive: 19.19 < Shareholder equity ratio, % of 24.48 <= 42.57
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PSTV quotes
Long-term PSTV plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.91MM | $5.82MM | $5.21MM |
| Operating Expenses | $18.23MM | $20.52MM | $20.51MM |
| Operating Income | $-13.32MM | $-14.70MM | $-15.30MM |
| Non-Operating Income | $0.01MM | $1.72MM | $-7.09MM |
| Interest Expense | $0.40MM | $0.18MM | $0.55MM |
| R&D Expense | $9.69MM | $10.58MM | $8.38MM |
| Income(Loss) | $-13.32MM | $-12.98MM | $-22.39MM |
| Net Income(Loss)* | $-13.32MM | $-12.98MM | $-22.39MM |
| Stockholders Equity | $-1.35MM | $-8.95MM | $4.00MM |
| Assets | $11.39MM | $6.63MM | $16.32MM |
| Operating Cash Flow | $-12.85MM | $-10.55MM | $-20.77MM |
| Capital expenditure | $0.16MM | $0.15MM | $0.07MM |
| Investing Cash Flow | $-0.16MM | $-4.11MM | $-0.85MM |
| Financing Cash Flow | $3.44MM | $6.19MM | $30.31MM |
| Earnings Per Share** | $-105,987.88 | $-48.86 | $-7.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.